Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRT6005 in moderate to severe osteoarthritis of the knee
NCT01357837Phase 2Completed
- Sponsor
- Tris Pharma
- Start
- May 2011
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of cebranopadol in knee osteoarthritis (OA), sponsored by Tris Pharma. Started May 2011; status: completed.
02
Drugs
cebranopadol
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT01357837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01357837.